Penn Pharma’s Large-Scale Commercial Manufacturing Suite Now Operational

Penn Pharma has revealed plans to invest a further £3 million to increase large-scale commercial manufacturing capabilities at its site in South Wales. Penn has declared that this new suite is operational less than 12 months after first announcing the plans.

This is in addition to the £14 million previously invested by Penn expanding its site with a purpose-built contained manufacturing facility, which opened in September 2013.

The new manufacturing suite includes granulation, tabletting and coating capability. This investment allows Penn Pharma to increase capacity for both current and future clients and improve its ability to service the growing market need for large-scale commercial outsourcing solutions.

Penn Pharma Chief Operating Officer, Mark Dean-Netscher commented: “We continue to grow and invest in new technology and our people. The decision to invest in additional capacity ensures we are able to offer our clients leading-edge technology across all manufacturing areas, continuously improve our service offering and exceed our clients’ expectations by offering the best possible service.”